PO:11:286 Design of a phase 3, randomised, double-blind, placebo-controlled parallel study to evaluate the efficacy and safety of enpatoran in cutaneous manifestations of lupus with or without systemic disease

tion occurred in all, lasting 8 months (median); one remained depleted for >25 years.Prednisone was used in twelve patients, the mean dose decreasing from 9.4 mg/day at baseline to 4.7 mg/day at 6 months, and remaining stable; two followed a steroid-sparing strategy.Mycophenolate /azathioprine were used in four /five respectively, both with progressive dose reductions.One patient was on methotrexate, discontinued after rituximab.Three mild infections occurred; none required hospitalization.No serious adverse events or deaths were observed.Conclusions A small subset of patients with SLE achieve prolonged remission after a single rituximab course, with normalized serologies and reduced treatment burden.Identifying this 'super-responder' phenotype may help guide patient selection for future B-cell depleting therapies.